Oriol Mirallas, Clinical Fellow in the Investigational Cancer Therapeutics (ICT) Department at the University of Texas MD Anderson Cancer Center, shared a post on X:
”Clinical trials mini symposium at AACR26
DKY709: IKFZ2 degrader +/- PS1 in pretreated ICI Novartis
3PR and 1CR 1CR beyond 2.5y DVR 41% Most common: ALT, rash and diarrhea, 2DLT in comb Peripheral neuropathy + QTc.”
Other articles featuring Oriol Mirallas.
